Download Citation
Article Source:
Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
Waldmann E,
Wu L,
Busygina K,
Altenhofer J,
Henze K,
et al.
(2022)
Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).
PLOS ONE 17(3): e0265838.
https://doi.org/10.1371/journal.pone.0265838